Tempus AI’s (TEM) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Tempus AI (NASDAQ:TEM) in a research report report published on Friday,Benzinga reports. They currently have a $75.00 price target on the stock.

Several other analysts also recently issued reports on the company. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. BTIG Research restated a “buy” rating and issued a $80.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. Finally, HC Wainwright reiterated a “buy” rating on shares of Tempus AI in a research report on Friday, July 24th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average price target of $68.92.

Tempus AI Trading Down 0.9%

Shares of Tempus AI stock opened at $43.87 on Friday. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The company has a market capitalization of $7.88 billion, a P/E ratio of -30.47 and a beta of 3.46. The company has a fifty day moving average of $51.40 and a 200 day moving average of $52.70.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 49.56% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the firm earned ($0.22) earnings per share. The business’s quarterly revenue was up 21.6% on a year-over-year basis. On average, sell-side analysts anticipate that Tempus AI will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In related news, EVP Andrew Polovin sold 8,703 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the transaction, the executive vice president directly owned 128,215 shares of the company’s stock, valued at approximately $5,650,435.05. This represents a 6.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 11,529 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $634,095.00. Following the transaction, the chief financial officer directly owned 114,866 shares of the company’s stock, valued at approximately $6,317,630. The trade was a 9.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 699,793 shares of company stock worth $33,763,231. 24.26% of the stock is currently owned by company insiders.

Institutional Trading of Tempus AI

A number of large investors have recently added to or reduced their stakes in TEM. JPL Wealth Management LLC bought a new position in shares of Tempus AI during the 3rd quarter valued at approximately $26,000. Los Angeles Capital Management LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at $27,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI in the third quarter worth $38,000. Danske Bank A S bought a new stake in Tempus AI in the third quarter worth $48,000. Finally, Sunbelt Securities Inc. purchased a new stake in Tempus AI during the third quarter valued at $52,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q2 results beat expectations. Tempus reported an adjusted loss of $0.04 per share, narrower than the $0.14 consensus loss and improved from a $0.22 loss a year earlier. Revenue increased 21.6% year over year to $382.5 million, modestly above estimates. Tempus AI Q2 earnings report
• Positive Sentiment: Management raised or reaffirmed strong 2026 growth expectations. Full-year revenue guidance is approximately $1.595 billion to $1.605 billion, supported by momentum in oncology diagnostics, data and modeling. Tempus also outlined a potential $400 million revenue uplift by 2028 tied to its xT CDx and xF products. Tempus revenue outlook
• Positive Sentiment: Analyst support remains favorable. Needham reaffirmed its Buy rating and set a $75 price target, implying substantial upside from recent trading levels. Needham analyst rating
• Negative Sentiment: The earnings beat did not fully resolve profitability concerns. Tempus remains unprofitable, with a negative net margin and analysts projecting a full-year loss. Revenue guidance is broadly consistent with expectations rather than a major upside surprise, contributing to the post-earnings reset. Tempus earnings call highlights
• Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares. The $10.5 million sale reduced his direct holdings by more than half. Although it was conducted under a pre-arranged Rule 10b5-1 plan, the transaction can still weigh on sentiment, particularly while the stock trades well below its 52-week high. Tempus CEO stock sale

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.